Understanding How Biomarkers Help Guide Treatment Decisions for Those with CLL / SLL

Each person who is diagnosed with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL / SLL) has a unique set of genetic biomarkers that make their type of the cancer unique to them. Biomarker testing will give you and your healthcare provider a better understanding of what treatments will work best for your disease type (predictive factors) and help to determine how aggressive your risk of the disease might be over time (prognostic factors).

In this session, we will discuss the most common biomarkers found in CLL / SLL, when and how to test for them using CLL Society’s Test Before Treat™ educational resource as a guide, which biomarker test results can change over time, and how some CLL / SLL treatments won’t work as well when certain biomarkers are present. Additionally, we will explore how testing for MRD (measurable residual disease) might serve as a guide for knowing when to start or stop treatment. Don’t miss this informative session on the role of biomarkers in CLL / SLL.

__________________________________________________________________________________________